TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01312103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based safety decision aid
Description: Participants will log into the the intervention website at baseline, 3 months, 6 months, and 12 months post baseline and receive:~* Setting of priorities for safety; a sliding bar allows participants to establish priorities by making pairwise comparisons of importance between factors.~* Danger Assessment; asks women to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger.~* Personalized action plan. Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented to her. The participant is given the option to print her results and the personalized plan.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Safety Plan
Description: Participants will log into a control website at baseline, 3 months, 6 months and 12 months post baseline. Website will include the usual services provided to IPV survivors looking for safety planning resources on the internet. Participants will receive:~* Danger Assessment, will see risk factors associated with lethal violence, but will not receive a score or feedback.~* A brief emergency safety plan with links to national and state domestic violence resources as well as a suicide resource.
Study: NCT04485390

Intervention type: OTHER
Intervention: Basic life support witn use of an AED before EMS
Description: BLS performance with use of an AED before arrival of EMS
Study: NCT01460693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Oral Imatinib 100mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Oral Dasatinib 100mg daily
Study: NCT03994848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spirometry Group
Description: Patients that are provided the incentive spirometer pre-operatively and instructed to use it for 4 cycles of 10 spirometry attempts on the day prior to surgery
Study: NCT04178603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise, insulin infusion
Description: Trial A: Acute one-legged exercise Trial B: Insulin infusion 4 hours after one-legged exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise, insulin infusion
Description: Trial A: Acute one-legged exercise Trial B: Insulin infusion 4 hours after one-legged exercise
Study: NCT02688777

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Backward Walking Training
Description: Backward Walking Training will occur both on a treadmill and overground. In brief, BWTraining will consist of 20-30 minutes of step training with a Body Weight Support and Treadmill system (BWST), rest periods provided as warranted, with manual assistance provided by trainers, followed by 15 minutes of overground gait training. A 20-30 min period of actual stepping is the goal for the intervention sessions on the treadmill with rest periods as needed. Each training session may last up to 1 hour and 30 minutes including time for warm-up, stretching, and cool down. Participants will be fitted with a harness around their hips and torso, which will be attached to an overhead support system directly above the treadmill. From a stationary position, the treadmill belt will gradually be increased in speed with intervention trainers assisting participant to step backward with their paretic leg, their non-paretic leg (if needed) and at the hips for weight-shift.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Backward Walking Training
Description: Backward Walking Training will occur both on a treadmill and overground. In brief, BWTraining will consist of 20-30 minutes of step training with a Body Weight Support and Treadmill system (BWST), rest periods provided as warranted, with manual assistance provided by trainers, followed by 15 minutes of overground gait training. A 20-30 min period of actual stepping is the goal for the intervention sessions on the treadmill with rest periods as needed. Each training session may last up to 1 hour and 30 minutes including time for warm-up, stretching, and cool down. Participants will be fitted with a harness around their hips and torso, which will be attached to an overhead support system directly above the treadmill. From a stationary position, the treadmill belt will gradually be increased in speed with intervention trainers assisting participant to step backward with their paretic leg, their non-paretic leg (if needed) and at the hips for weight-shift.
Study: NCT03066947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SV-BR-1-GM
Description: See above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Low dose pre-treatment to reduce regulatory T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b
Description: Low dose given in the vaccine site to boost the immune response
Study: NCT02718144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol
Description: Estetrol formulated in tablets, in escalating doses, will be investigated in patients with estrogen receptor positive (ER+) locally advanced or metastatic breast cancer.
Study: NCT00971815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: first week: 10mg/day. Then, treatment with 20mg/day is continued throughout a 3 months period of time.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1/2 pill pr day first week, then 1 pill pr. day throughout a 3 months treatment period (90-118 ± 7days)
Study: NCT01364844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-7423
Description: oral capsule 1mg, 8mg, 48mg, and 80mg strengths administered once daily
Study: NCT04773106

Intervention type: DEVICE
Group type: OTHER
Intervention: ARGOS-SC suprachoroidal pressure sensor
Description: The ARGOS-SC pressure sensor was additionally used implanted during routine local intraocular pressure lowering procedures in patients in patients with glaucoma undergoing non-penetrating glaucoma surgery in the earlier ARGOS-SC01 study.
Study: NCT02124317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel
Description: nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21 day cycle. Number of cycles: 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 is orally administered (40-60 mg according to the body surface, twice a day) on day 1-14 of each 21 day cycle. Number of cycles: 6 cycles.
Study: NCT02795702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training
Description: Cognitive training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: training
Description: Cognitive training
Study: NCT02336217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group instructions for glucose management via App
Description: The Experimental Group receives individually calculated instructions for glucose management management via the App.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator general instructions
Description: The Placebo Comparator Group receives general instructions but not the complete management algorithm
Study: NCT04254172

Intervention type: DEVICE
Intervention: Activity Monitor
Description: Wrist and ankle sensors to be worn continuously for 2-week intervals.
Study: NCT03792906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine 6 mcg
Description: An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine 10 mcg
Description: An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine infusion
Description: Prophylactic norepinephrine infusion will be started after subarachnoid block.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Description: Prophylactic norepinephrine infusion will be started after subarachnoid block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrochloride
Description: Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride
Description: Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg.
Study: NCT04651062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endocuff
Description: Endocuff is a relatively new device which is intended to be attached to the end of the colonoscope.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no endocuff
Description: colonoscopy is performed without endocuff.
Study: NCT03515330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Intervention
Description: The mHealth application will allow liver transplant recipients to see their medication regimen, record a video of themselves taking every dose, report side effects or symptoms, visualize their treatment progress, and access educational content. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
Study: NCT04420104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block
Description: ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iv analgesia
Description: iv contromal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iv analgesia
Description: iv contromal
Study: NCT03388164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram + RT2CK17
Description: Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram + Placebo
Description: Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
Study: NCT02210039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SECM Probe
Description: Imaging of the esophagus using SECM probe and system.
Study: NCT00346697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid administration
Description: LOVAZA 1 gram capsules, 4 capsules daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn-oil placebo
Study: NCT02731235

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity training
Description: high intensity training 5 days a week for 12 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: prophylactic stroke medication
Description: Usual care medication for stroke prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prophylactic stroke medication
Description: Usual care medication for stroke prophylaxis

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Recommendations for lifestyle changes
Description: Advise on diet, alcohol, smoking and exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recommendations for lifestyle changes
Description: Advise on diet, alcohol, smoking and exercise
Study: NCT04510961

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paraffin baths therapy
Description: Patients in treatment group will receive paraffin wax baths for five days per week for 12 weeks. Prepare the paraffin device and blocks of paraffin wax. Put the paraffin wax blocks inside the tank and set the thermostat 35 to 40◦C. Melting paraffin was taken from 90 to 120 minutes. Adjust the suitable temperature for each patient before immersion of patient's hand. Submerge patient's hand completely for three to four seconds then withdraw it
Study: NCT04186143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed Cinetic Chain Exercises
Description: Sit to stand, mini squat, anterior lunge, step up exercises are performed as Closed Cinetic Chain Exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open Kinetic Chain Exercises
Description: Isometric quadriceps, isotonic quadriceps, hip extension and hip adduction exercises are performed as Open Kinetic Chain Exercises.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Control Group was followed up by conservative treatment and home program for 12 weeks and they were asked to apply the home program three days in a week. Exercise brochure was handed out for home program. Quadriceps strength and harmstring stretch exercises were applied.
Study: NCT04287790

Intervention type: BEHAVIORAL
Intervention: audit and feedback, educational meetings, and academic detailing to promote medication receipt
Description: Our implementation intervention will incorporate the following strategies: 1) Formation of an alcohol-related care working group. This voluntary working group will consist of members of the research team and volunteer health professionals from YNHH. The group with supervise and support the other intervention components. 2) We will develop medication for alcohol use disorder marketing (posters and buttons) materials and educational (pamphlet) materials and distribute these materials to health professionals. 3) Building on the existing infrastructure and collaboration, the research team will assist in revising existing alcohol-related care daily monitoring systems to support auditing and feedback on the adoption of medications for alcohol use disorder at YNHH. 4) The research team will hold educational meetings and educational outreach visits (academic detailing) when invited during regular noon conferences and team meetings.

Intervention type: DRUG
Intervention: Acamprosate, naltrexone, or disulfiram
Description: Increased receipt of medications for alcohol use disorder facilitated by the implementation intervention.

Intervention type: DRUG
Intervention: Acamprosate, naltrexone, or disulfiram
Description: Increased receipt of medications for alcohol use disorder facilitated by the implementation intervention.
Study: NCT01387997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrosensing antibody probing system (e- Ab sensor)
Description: Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-high risk HPV and its antigen (high-risk HPV) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (high-risk HPV) in the test specimens. From assessment of the electric signature of semiconductive anti- high-risk HPV antibodies, the eABprobe could offer sensitive detection and precise quantification of high-risk HPV.
Study: NCT03588585

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tension
Description: Tension applied to catheter and taped firmly to leg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NO TENSION
Description: Foley balloon will be taped loosely to the leg and not placed on tension. All other care will remain the same
Study: NCT02567578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852 0.1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852 0.25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852 0.5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01907711

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture.
Description: Who tried the insertion and manipulation between 8 - 12 needles with guide applied at different points of the body, individually selected and customized, after the insertion, the acupoint stimulation is done through manipulation of de needle sleeve to achieve at each point the sensation known as De Qi.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture.
Description: Who tried the insertion and manipulation between 8 - 12 needles with guide applied at different points of the body, individually selected and customized, after the insertion, the acupoint stimulation is done through manipulation of de needle sleeve to achieve at each point the sensation known as De Qi.
Study: NCT04154189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 14 milligrams per square meter (mg/m\^2) capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until disease progression (PD), development of unacceptable toxicity, participant request, withdrawal of consent, or discontinuation of study by the sponsor.~An extemporaneous suspension of lenvatinib capsules may be used for participants unable to swallow capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Ifosfamide 3000 milligrams per square meter per day (mg/m\^2/day) intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 3000 milligrams per square meter per day (mg/m\^2/day) intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2/day intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2/day intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Lenvatinib 14 mg/m\^2 capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until the next PD (per response evaluation criteria in solid tumors \[RECIST\] 1.1 as assessed by investigator), development of unacceptable toxicity, participant request, or withdrawal of consent, whichever occurs first.
Study: NCT01559857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 30mg once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Placebo
Study: NCT04048772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM IVF
Description: The intervention will be three 1-1.5 hour interactive sessions that are scheduled throughout the participant's first in vitro fertilization cycle. These sessions will provide additional time for discussion about treatment with providers, learning opportunities on topics of interest to fertility patients, and stress reduction techniques.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Patients will receive the standard of care IVF treatment at the University of Iowa.
Study: NCT01940796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Up to five dose levels will be tested in cohorts of 3-6 participants each. Once the maximum tolerated dose (MTD) is established, 10 more participants will be treated at the MTD for analysis of efficacy.
Study: NCT01672671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin, Paclitaxel, Cisplatin
Description: Doxorubicin 25 mg/m2, IV weekly. Number of Cycles: 8 Paclitaxel 100 mg/m2, IV weekly. Number of Cycles: 8. Cisplatin 30 mg/m2, IV weekly. Number of Cycles: 8.
Study: NCT03553355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared Laser Moxibustion
Description: We will use SX10-C1 laser moxibustion devices (Shanghai Wonderful Opto-Electrics Tech Co Ltd, Shanghai, China) for the ILM and SILM groups. Four laser probes will be synchronously aligned with 4 points (tST36 (bilateral), CV4, and CV6 acupoints) and we will irradiate each acupoint 2 cm away from the skin surface for 20 minutes. Each patient will receive this treatment twice per week for six weeks (12 sessions total).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Infrared Laser Moxibustion
Description: The sham laser moxibustion instrument appears to be identical as the real one.
Study: NCT02112071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Blended supervised-home based walking program 3-4 times per week for at least 30 minutes.
Study: NCT03544177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR-Walking
Description: Participants will perform 12 training sessions over 6 weeks, including a 10-minute warm up and cool down period. Patients will perform 5 six-minute bouts of over ground intermittent walking exercise (1-minute walk/rest) with their habitual walking device at a prescribed speed maintained by a metronome, starting from 60 steps/minute. A fixed resting period of 3 minutes will follow each walking bout. During walking, participants will wear BFR bands at both tights. Before every walking bout, the bands will be tightened at a low intensity (max 40% of blood systolic pressure) and untied at the end of every walking bout when patients will be asked to grade their RPE (Borg Scale). Walking speed will be weekly increased by 3 steps/minute, if the previous level was well-tolerated by the patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Participants will perform 12 training sessions over 6 weeks. Patients will perform assisted over-ground walking for a total of around 40 minutes, inserted between a 10-minute warm-up and cool-down period. The patient will be encouraged by the same experienced physiotherapist to walk back and forth on 50-meter indoor flat corridor with their habitual walking device. Patient will be asked to walk without stopping until reaching an effort corresponding to a value of 8 out of 10 of the rating of perceived exertion (Borg scale). When the exertion level is reached, the patients will be allowed to rest sitting on a chair if necessary; after a suitable rest period, when patients express sufficient desire to start again, the training will restart